date,title,source
Nov-14-18,Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results,GlobeNewswire
Dec-03-18,Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting,GlobeNewswire
Feb-21-19,Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units,GlobeNewswire
Feb-22-19,Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units,GlobeNewswire
Mar-08-19,Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units,GlobeNewswire
Mar-11-19,Trillium: 4Q Earnings Snapshot,Associated Press
Mar-11-19,Trillium Therapeutics Reports Annual Financial and Operating Results,GlobeNewswire
Mar-27-19,Trillium Therapeutics to Unveil its STING Agonist Program at the AACR Annual Meeting 2019,GlobeNewswire
Mar-27-19,Four Healthcare Stocks Picking Up Speed on Wednesday,ACCESSWIRE
Apr-02-19,Trillium Therapeutics Expands Immuno-Oncology Pipeline With STING Agonist Program,GlobeNewswire
Apr-08-19,Trillium Therapeutics to Present at Investor Conferences in April,GlobeNewswire
Apr-11-19,Trillium Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,GlobeNewswire
